News

Novo Nordisk (NVO) closed the most recent trading day at $38.17, moving 3.12% from the previous trading session.

Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged. Eli Lilly and Novo fell.

No one expects a lot of growth from Novo Nordisk anymore -- not even Novo Nordisk itself.

European stock markets closed higher Monday as oil prices tumbled and investors looked ahead to US P

Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...

On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has "newfound optimism on the retailer's strategy to elevate brand awareness" and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations.

Novo Nordisk took the stage at its own capital markets day and said something that sent its stock tumbling 7%, yet its closest rivals barely flinched. What the company revealed about its future tells investors exactly how much trouble the Ozempic empire may be in.

Warner Bros. Discovery and Paramount Skydance shares rose in premarket trading as investors focused on the merger talks.

The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity

The Danish drugmaker pledged to launch 5 multi-blockbuster drugs by 2030 and grow revenue in line with peers, but investors wanted more

Novo Nordisk (NYSE:NVO) shares declined 6% on Monday after the Danish pharmaceutical company presented its long-term strategy and financial ambitions at a capital markets day in London. The company expects compound annual revenue growth between 2026 and 2030 to be in line with that of its industry peers, while maintaining a broadly stable operating margin.

Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports.

NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.

Novo Nordisk (NVO) closed the most recent trading day at $41.67, moving 2.02% from the previous trading session.

Anthropic's models may shorten research workflows, but neither company disclosed financial terms or productivity targets.

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

Novo Nordisk Shares Fall as Wall Street Questions Its Next Growth Move

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD

Novo Nordisk dropped 'Nordisk' from its name, betting a culture reset can help it retake share from Eli Lilly.

The Danish drugmaker is shortening its name to Novo, but it will take more than a lean rebrand to win back Wall Street.

Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.

One date in the next decade is quietly doing all the work in Wall Street’s newest bear case.

Morgan Stanley sees Eli Lilly taking share before semaglutide's patents even become the bigger issue.

Morgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook

Morgan Stanley keeps Novo price target at 250 DKK

Novo Nordisk (NVO) closed the most recent trading day at $44.01, moving 1.23% from the previous trading session.

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th

Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index falling 2.4% and the St

Germany is the first EU pill market, but pen-equivalent pricing means convenience--not discounting--must win adoption.

Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 Danish krone against a last close of 292.4 Danish krone. Analyst Emmanuel Papadakis published Citi's weekly IQVIA tracker of Novo's GLP-1 assets, using retail...